These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29684788)

  • 1. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
    Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
    Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
    Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
    Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
    Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
    [No Abstract]   [Full Text] [Related]  

  • 5. Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients.
    Bianco A; Mari PV; Larici AR; Lucchini M; Nociti V; Losavio FA; De Fino C; Cicchetti G; Coraci D; Richeldi L; Mirabella M
    Mult Scler Relat Disord; 2020 Jan; 37():101450. PubMed ID: 31675637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
    Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
    Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
    Metz I; Rieckmann P; Kallmann BA; Brück W
    Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
    Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
    BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.
    Blasco MR; Ramos A; Malo CG; García-Merino A
    J Neurol; 2017 Jan; 264(1):168-169. PubMed ID: 27888417
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
    Saarela M; Senthil K; Jones J; Tienari PJ; Soilu-Hänninen M; Airas L; Coles A; Saarinen JT
    Neurology; 2018 May; 90(18):849-851. PubMed ID: 29602914
    [No Abstract]   [Full Text] [Related]  

  • 15. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.
    Lau AY; Lui GCY; Chan KP; Au C; Mok VCT; Ziemssen T
    Mult Scler Relat Disord; 2020 Feb; 38():101503. PubMed ID: 31743846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
    Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
    Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    di Ioia M; Farina D; di Tommaso V; Travaglini D; Pietrolongo E; Onofrj M; de Luca G
    Mult Scler; 2018 May; 24(6):813-815. PubMed ID: 29359617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
    Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
    Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
    Hoffman BM; Zeid NA; Alam U; Caress JB
    Mult Scler Relat Disord; 2019 Jan; 27():131-132. PubMed ID: 30384197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
    Richter S; Wagner B; Celius EG
    J Neurol; 2019 May; 266(5):1270-1271. PubMed ID: 30805797
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.